Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Guaiacol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaiacol SCHEMBL28956723 | 0.93 | CA1 (0.60) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL1824093 | 0.91 | TSHR (0.62) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL4089861 | 0.89 | CA1 (0.69) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL4085621 | 0.88 | TSHR (0.58) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL21542 | 0.88 | CA1 (0.82) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL27636740 | 0.87 | TSHR (0.67) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL11482294 | 0.87 | TSHR (0.67) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL4095961 | 0.87 | TSHR (0.56) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL4090352 | 0.87 | TSHR (0.56) | CA1TP53TSHRCA2LMNA | |
| Guaiacol SCHEMBL5665553 | 0.86 | CA1 (0.78) | CA1TP53TSHRCA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | disclosed |
| CN-101969791-B | seasoning method | GIVAUDAN SA | 2013-10-30 | — | — | CN | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| CN-101969791-A | seasoning method | GIVAUDAN SA | 2011-02-09 | — | — | CN | disclosed |
| EP-2237683-A2 | METHOD OF FLAVORING | Givaudan SA (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092176-A2 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186138-A1 | Method of Flavoring | TAS2R5, TAS2R50, TAS2R10 | CA1 1848/4885TP53 4628/4885TSHR 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.